Similar articles

• Paclitaxel, carboplatin, and hexamethyl-melamine (taxchex) as first-line therapy for ovarian cancer.

  Hartenbach EM, Harris LS, Bailey HH, Grosen EA, Larrison E, Chen D, Twiggs LB, Schink JC. Hartenbach EM, et al. Cancer J Sci Am. 1999 Nov-Dec;5(6):348-55. Cancer J Sci Am. 1999. PMID: 10606476
• [Adverse effect of paclitaxel plus carboplatin combination therapy related to administration schedule in patients with ovarian cancer].

  Fuse K, Tanaka T, Kagaya H, Suzuki T, Kimura A. Fuse K, et al. Gan To Kagaku Ryoho. 2001 Sep;28(9):1295-7. Gan To Kagaku Ryoho. 2001. PMID: 11579644 Japanese. No abstract available.
• A comparative study on hematological effects of carboplatin plus cyclophosphamide and carboplatin plus paclitaxel chemotherapy for the first line treatment of epithelial ovarian cancer.

  Vapattanawong P. Vapattanawong P. J Med Assoc Thai. 2006 Sep;89(9):1357-61. J Med Assoc Thai. 2006. PMID: 17100369
• Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.

  Ozols RF. Ozols RF. Semin Oncol. 2000 Jun;27(3 Suppl 7):3-7. Semin Oncol. 2000. PMID: 10952119 Review.
• Paclitaxel (T) and carboplatin (CB) in ovarian cancer patients in Dharmais National Cancer Hospital, 1993-1999.

  Zakifman, Djoerban Z, Soemanadi M, Nasdaldy, Dwipoyono B, Sjamsuddin S. Zakifman, et al. Gan To Kagaku Ryoho. 2000 May;27 Suppl 2:560-2. Gan To Kagaku Ryoho. 2000. PMID: 10895210 Review. No abstract available.